Higher price of Covaxin in private markets needed to sustain costs: Bharat Biotech

Supply to the government of India at ₹150 per dose is a non-competitive price and clearly not sustainable in the long run, the company said

Comments

Popular posts from this blog

Infosys lays off hundreds after failing internal assessments in Mysuru

Greater Bengaluru Committee proposes seven municipal corporations

Congress groomed me not to sit at home: Shivakumar